The Immune System
How the body distinguishes self from non-self, eliminates invading pathogens, and remembers previous infections to respond faster the next time. Phagocytes for immediate defence; B- and T-lymphocytes for specific, adaptive immunity. Antibodies as molecular targeting devices — from the precise Y-shape that recognises one antigen, to monoclonal antibodies engineered for diagnosis and therapy.
The immune system
The immune system defends the body against pathogens through two cooperating layers: an immediate, non-specific response carried out by phagocytes, and a delayed but specific response carried out by lymphocytes. The lymphocyte response also produces memory cells that respond faster on second exposure — the basis of long-term immunity.
Two layers of defence
- Acts the same way against any pathogen
- Rapid — minutes to hours
- No memory of past encounters
- Includes physical barriers (skin, mucus), chemical barriers (lysozyme in tears, stomach acid), and phagocytosis by macrophages and neutrophils
- Targeted to a particular pathogen via its antigens
- Slower on first exposure (~10–14 days for full response)
- Has memory — second exposure responds faster and more strongly
- Carried out by B-lymphocytes (antibody production) and T-lymphocytes (cell-mediated response)
Phagocytosis — macrophages and neutrophils
Phagocytosis is the engulfing and digestion of pathogens by phagocytes. Two main phagocytic cells are required for the syllabus:
| Feature | Neutrophils | Macrophages |
|---|---|---|
| Origin | Made in bone marrow; mature in blood | Made in bone marrow as monocytes; differentiate into macrophages in tissues |
| Lifespan | Short (1–3 days) | Long (weeks to months) |
| Nucleus | Multi-lobed | Single, often kidney-shaped |
| Pathogens engulfed | Few before dying (often die after phagocytosing several) | Many over the cell's long lifetime |
| Role in adaptive immunity | Limited | Antigen-presenting cells — display digested pathogen antigens on surface to activate T-helper cells |
| First responder? | Yes — arrive at infection sites first | Resident in tissues; coordinate longer-term response |
- Recognition / chemotaxis: chemicals released by pathogens or by damaged tissue attract phagocytes (chemotaxis)
- Engulfment: phagocyte's plasma membrane extends around the pathogen and pinches off — the pathogen is now enclosed in a vesicle inside the phagocyte called a phagosome (this is endocytosis)
- Fusion: a lysosome (Topic 1) fuses with the phagosome, forming a phagolysosome
- Digestion: hydrolytic enzymes (including lysozyme) digest the pathogen to its constituent biomolecules
- Antigen presentation (macrophages especially): pathogen antigens are processed and displayed on the macrophage's surface bound to membrane proteins. The macrophage is now an antigen-presenting cell (APC)
- Waste removal: harmless products of digestion are released by exocytosis or used by the phagocyte
Antigens — self vs non-self
An antigen is any substance that the immune system can recognise and respond to — usually a protein or glycoprotein on the surface of cells or pathogens (Topic 4.1.3 cell membrane glycoproteins).
Antigens present on the body's own cells. Lymphocytes that would react against self antigens are normally destroyed during development — so the immune system tolerates self antigens and does not attack the body's own cells (a process called “self-tolerance”).
Failure of self-tolerance causes autoimmune disease (e.g. rheumatoid arthritis, type 1 diabetes).
Antigens not normally present in the body — on pathogens, transplanted tissues, abnormal (cancer) cells. Lymphocytes that recognise non-self antigens trigger a specific immune response.
Pathogen antigens vary between species and even between strains, allowing the immune system to recognise specific invaders.
The primary immune response
The primary immune response is the body's first encounter with a particular pathogen. It is slow (~10–14 days to peak) and may be insufficient to prevent symptoms, but it sets up immune memory for future protection.
- Pathogen enters and is engulfed by a macrophage (phagocytosis); pathogen antigens displayed on macrophage surface (antigen-presenting cell)
- T-helper cell with a receptor complementary to the displayed antigen binds the macrophage and is activated; the activated T-helper releases cytokines — small signalling proteins
- Cytokines from T-helper cells trigger three parallel responses:
- Activate B-lymphocytes with complementary surface antibodies (clonal selection)
- Activate T-killer (cytotoxic) cells that recognise infected body cells displaying pathogen antigens
- Activate further macrophages, enhancing phagocytosis
- Activated B-cells undergo clonal expansion (rapid division by mitosis), differentiating into:
- Plasma cells: short-lived but secrete enormous quantities of free antibody (~2,000 antibody molecules per second per plasma cell)
- Memory B-cells: long-lived, persist for years; ready for any future encounter
- Antibodies bind pathogen antigens, leading to neutralisation, agglutination, and opsonisation (covered in 11.2)
- T-killer cells locate and destroy body cells that are infected (e.g. by virus) and display the pathogen's antigens, by inducing apoptosis or releasing cytotoxic chemicals
- Pathogen is cleared; most plasma cells and effector T-cells die; memory B- and T-cells remain
T-helper cells are the coordinators of the adaptive immune response — they activate B-cells, T-killer cells, and macrophages. Without T-helpers, the specific immune response collapses.
This is why HIV/AIDS (Topic 10) is so devastating: HIV specifically destroys T-helper cells. As T-helper numbers fall, every part of the adaptive immune system loses its coordinator, and the body becomes vulnerable to infections it would normally resist.
Immune cell roles — summary
| Cell | Type of immunity | Main role |
|---|---|---|
| Neutrophils | Non-specific | Phagocytosis — first responders to bacterial infection |
| Macrophages | Non-specific + bridge to specific | Phagocytosis + antigen presentation to T-helper cells |
| T-helper cells | Specific (cell-mediated) | Activate B-cells, T-killer cells, and macrophages via cytokines |
| T-killer (cytotoxic) cells | Specific (cell-mediated) | Destroy infected body cells displaying pathogen antigens |
| B-lymphocytes | Specific (humoral) | Activated by T-helpers; differentiate into plasma cells |
| Plasma cells | Specific (humoral) | Secrete free antibodies in huge quantities; short-lived |
| Memory cells | Specific (long-term) | Persist for years; respond rapidly on second exposure |
The secondary immune response and long-term immunity
If the same pathogen is encountered again, the response is dramatically different. Memory cells recognise the antigen immediately and trigger rapid clonal expansion of effector cells. The result is the secondary immune response:
- Faster: significant antibody production within 1–3 days, vs ~10–14 days for primary
- Larger: peak antibody concentration may be 10–100 times higher than the primary peak
- Longer-lasting: persists for weeks or longer
- Symptom-free in most cases — the pathogen is destroyed before it multiplies enough to cause illness
Primary vs secondary — comparison
| Feature | Primary response | Secondary response |
|---|---|---|
| Trigger | First exposure to a particular antigen | Subsequent exposure to the same antigen |
| Time to peak antibody concentration | ~10–14 days | ~3–5 days |
| Peak antibody concentration | Lower | Much higher (~10× or more) |
| Cells responsible for fast onset | Naive B- and T-cells (must search for matching receptor) | Memory B- and T-cells (already specific) |
| Symptoms? | Usually present (illness) | Usually absent (immunity) |
| Antibody class predominant | IgM initially, then IgG | Mainly IgG immediately |
This is the basis of long-term immunity. After natural infection or vaccination, memory cells persist and ensure that any future encounter with the same antigen produces a fast, strong, often symptom-free response.
Which sequence correctly describes the steps of phagocytosis?
- A. Engulfment → chemotaxis → lysosome fusion → digestion
- B. Chemotaxis → engulfment to form phagosome → lysosome fusion → digestion
- C. Chemotaxis → lysosome fusion → engulfment → digestion
- D. Lysosome fusion → chemotaxis → engulfment → digestion
A person is infected with a pathogen for the first time.
(a) Describe the role of macrophages in initiating the specific immune response. [3]
(b) Explain how T-helper cells coordinate the immune response. [3]
(c) Explain why a person who recovers from a particular infection rarely catches the same disease again. [3]
(a) Macrophage role [3 marks]
- The macrophage engulfs the pathogen by phagocytosis [1]
- The pathogen is digested inside a phagolysosome by hydrolytic enzymes [1]
- Antigens from the pathogen are displayed on the macrophage surface (it becomes an antigen-presenting cell), allowing T-helper cells to recognise and respond to the specific pathogen [1]
(b) T-helper coordination [3 marks]
- A T-helper cell with a receptor complementary to the displayed antigen binds the macrophage and is activated [1]
- The activated T-helper cell releases cytokines (signalling proteins) [1]
- The cytokines activate B-cells with complementary antibodies (which become plasma cells), activate T-killer cells (which destroy infected body cells), and stimulate further phagocytosis by macrophages [1]
(c) Long-term immunity [3 marks]
- The first infection produces memory B- and T-cells specific to the pathogen's antigens, which persist for years [1]
- On subsequent exposure, memory cells immediately recognise the antigen and undergo rapid clonal expansion [1]
- The secondary immune response is much faster and larger than the primary, producing high antibody concentrations within a few days — the pathogen is destroyed before symptoms develop [1]
Antibodies and vaccination
Antibodies (immunoglobulins) are the soluble molecules that target specific antigens for destruction. Their molecular structure is engineered for specific recognition and effective elimination — and that same specificity makes them extraordinarily valuable as monoclonal antibodies: laboratory-produced antibodies of a single specificity used in diagnosis, therapy, and research.
Antibody structure
An antibody is a Y-shaped glycoprotein with quaternary structure (Topic 2.3) made of four polypeptide chains:
- Two heavy chains (long; centre of the Y plus part of each arm)
- Two light chains (short; tip of each arm only)
- The four chains are held together by disulfide bonds (between cysteine residues)
Each antibody has two functional regions:
The tips of the two arms of the Y. The amino acid sequence here is different in each antibody, producing a unique 3D shape (binding site) that is complementary to one specific antigen.
Each antibody has two identical antigen-binding sites — one at each arm tip. Both are specific to the same antigen.
The stem and lower portions of the arms. The amino acid sequence is the same across all antibodies of the same class (e.g. all IgG antibodies share the same constant region).
The constant region is recognised by other components of the immune system (phagocytes, complement system) — allowing the antibody to recruit them once it has bound an antigen.
Between the variable and constant regions. Provides flexibility allowing the two binding sites to swing apart or together — important for binding antigens at variable distances on a pathogen surface.
Functions — structure related to action
Antibody actions all depend on the antibody binding its specific antigen via the variable region. The constant region then determines how the bound complex is processed:
The antibody binds an antigen on the pathogen surface or a toxin molecule, blocking the pathogen from binding to host cells (e.g. preventing a virus from entering a host cell), or blocking the toxin's active site.
Each antibody has 2 binding sites — allowing it to bind antigens on two different pathogens simultaneously. As multiple antibodies do this, pathogens are clumped together, immobilising them and making them easier to phagocytose. Particularly effective against bacteria with multiple surface antigens.
The antibody coats the pathogen surface; the antibody's constant region is recognised by phagocytes' surface receptors. This marks the pathogen for phagocytosis and dramatically increases the rate at which phagocytes engulf it.
The antibody-antigen complex triggers the complement cascade — a set of plasma proteins that ultimately punch holes in the pathogen's plasma membrane (causing lysis) and release inflammatory signals.
Monoclonal antibodies — the hybridoma method
Monoclonal antibodies (mAbs) are antibodies made by a single clone of B-cells — so all the antibody molecules are identical and bind the same antigen with the same specificity. The challenge: a single B-cell from an animal will not divide indefinitely in culture, but a single antibody-producing cell line is needed to make commercial quantities.
The solution — the hybridoma method — combines the antibody-making ability of a B-cell with the indefinite growth ability of a myeloma (cancer) cell:
- Inject the target antigen into an animal (typically a mouse). The mouse mounts an immune response, producing many B-cell clones, each making antibodies specific to a different antigen on the injected material
- After ~6 weeks, extract spleen cells from the mouse (the spleen is rich in activated B-cells)
- Fuse the spleen B-cells with myeloma cells (a cancerous cell line that divides indefinitely in culture) using a fusion agent such as polyethylene glycol (PEG). Some fusions produce hybridoma cells — combining the antibody-producing ability of the B-cell with the immortality of the myeloma cell
- Select hybridoma cells using a special medium that kills unfused cells; only successful hybridomas survive
- Screen each hybridoma to find one producing the desired antibody (i.e. an antibody specific to the antigen of interest)
- The selected hybridoma is cultured in large quantities, all clones being genetically identical — producing a continuous supply of identical (monoclonal) antibodies
A natural immune response produces polyclonal antibodies — many different antibodies recognising different antigens on the same pathogen. For research and clinical use, having many different antibodies is often a problem because each interacts differently. Monoclonal antibodies all behave identically, making them reliable, reproducible reagents.
Monoclonal antibodies in diagnosis and treatment
The specificity and purity of monoclonal antibodies make them powerful tools in medicine. Both applications rely on the antibody's ability to bind one specific molecule among countless others:
Home pregnancy tests detect human chorionic gonadotrophin (hCG) in urine using monoclonal antibodies specific to hCG. A coloured line appears if hCG is present (produced by an early pregnancy). This test is fast, simple, accurate, and can be done at home.
ELISA (enzyme-linked immunosorbent assay) uses monoclonal antibodies linked to enzymes that produce a colour change. Used to detect specific molecules in samples — including pathogen antigens (e.g. HIV antigen tests) and disease biomarkers (e.g. PSA in prostate cancer screening).
Some cancer cells display unique surface proteins. Monoclonal antibodies engineered to bind these proteins can:
- Block growth signals: e.g. trastuzumab binds HER2 protein on some breast cancers, blocking the growth signal
- Mark cancer cells for immune destruction: rituximab binds B-cell lymphoma cells, leading to their destruction
- Deliver toxic drugs: an antibody can be linked to a cytotoxic drug, delivering the drug specifically to cancer cells while sparing healthy tissue
Autoimmune disease: monoclonal antibodies that block specific signalling molecules (e.g. anti-TNF antibodies for rheumatoid arthritis, Crohn's disease).
Infectious disease: monoclonal antibodies were developed and used during the COVID-19 pandemic for treatment and prevention in high-risk patients.
Transplant medicine: monoclonal antibodies suppress immune rejection of transplanted organs.
Conventional drugs often affect many cell types — producing side effects. Monoclonal antibodies bind only their specific target molecule, so off-target effects are much lower. This specificity is the key benefit. The cost is high (production is expensive) and some patients develop antibodies against the monoclonal antibody (especially when derived from mouse cells — modern mAbs are often "humanised" to reduce this).
Active vs passive, natural vs artificial
Immunity can be classified along two axes:
| Natural | Artificial | |
|---|---|---|
| Active (body makes its own antibodies; long-lasting due to memory cells) | Recovery from natural infection | Vaccination — antigens delivered without the disease |
| Passive (body receives ready-made antibodies; immediate but short-lived — no memory cells produced) | Antibodies from mother to fetus across placenta; antibodies in colostrum and breast milk | Injection of antibodies (e.g. anti-tetanus immunoglobulin after a deep wound; anti-snake venom) |
The body's own B-cells make antibodies in response to an antigen (whether from a natural infection or a vaccine). Memory B- and T-cells are produced. Long-term — immunity lasts years or for life.
Slower onset (~10–14 days from first exposure) but durable.
The body receives antibodies that someone else (or another animal) has already made. No memory cells are produced — once the antibodies are degraded (weeks to months), immunity is lost.
Immediate onset — useful when rapid protection is needed (e.g. after exposure to a serious pathogen, or for newborns who cannot yet make antibodies efficiently).
Vaccines
A vaccine contains antigens that stimulate the immune response without causing the disease. The immune system responds with a primary response — producing memory cells — so that on later exposure to the actual pathogen, the secondary response prevents illness.
Living but weakened (attenuated) form of the pathogen, unable to cause disease in a healthy person. Stimulates a strong immune response. Examples: measles, mumps, rubella (MMR vaccine), oral polio.
Pathogen killed by heat or chemicals. Cannot replicate. Generally weaker response than live vaccines — often needs boosters. Examples: inactivated influenza vaccine, hepatitis A.
Subunit: contains only key antigens of the pathogen — often produced by recombinant DNA technology (e.g. hepatitis B surface antigen). Toxoid: chemically modified bacterial toxin — e.g. tetanus, diphtheria. mRNA: a newer class delivering mRNA encoding the pathogen antigen, with the body's own cells then producing the antigen (e.g. some COVID-19 vaccines).
Vaccination programmes and disease control
National and international vaccination programmes aim to control or eliminate infectious diseases at the population level. They depend on:
When a high enough percentage of the population is immune (through infection or vaccination), the pathogen cannot easily spread between people because too few susceptible individuals remain. Even unvaccinated people are then protected indirectly.
The threshold for herd immunity varies by disease — highly contagious pathogens (e.g. measles) need ~95% population immunity; less contagious pathogens have lower thresholds.
Some people cannot be vaccinated — very young infants, severely immunocompromised people, those with severe vaccine allergies. Herd immunity protects them by reducing the chance they encounter an infected person at all.
If immunity is sustained globally and the pathogen has no animal reservoir, eradication is theoretically possible. Smallpox was eradicated in 1980 through global vaccination — a triumph of public health. Polio eradication is close in many regions.
For new pathogens (e.g. SARS-CoV-2 in 2019), rapid vaccine development and equitable global distribution are essential. mRNA vaccine platforms have shortened development timelines significantly. Maintaining global vaccination capacity for outbreak response is now a public health priority.
Some individuals do not respond strongly to a vaccine (e.g. due to immune deficiency or age-related decline); others may have a weakened response that fades over time, requiring boosters. Some pathogens (e.g. influenza) mutate rapidly so that previous vaccines and immunity become less effective — this is why flu vaccines are reformulated annually. Herd immunity remains essential for protecting those whose own immune response is insufficient.
In the hybridoma method, why are B-cells fused with myeloma cells?
- A. To increase the number of antigens the cells can recognise
- B. To convert the cells into immune cells that can attack pathogens
- C. To combine the antibody-producing ability of the B-cell with the indefinite division ability of the myeloma cell
- D. To prevent the antibodies from being recognised as foreign in the patient
Antibodies have a precise molecular structure that allows them to combat pathogens.
(a) Describe the molecular structure of an antibody. [3]
(b) Explain how the structure of an antibody is related to TWO of its functions. [4]
(c) Explain why a mother passing antibodies to her child via breast milk gives the child only short-term protection. [2]
(a) Antibody structure [3 marks]
- Y-shaped glycoprotein with quaternary structure made of four polypeptide chains: two heavy and two light chains [1]
- The four chains are held together by disulfide bonds [1]
- Each antibody has two variable regions (one at the tip of each arm) with a unique amino acid sequence forming a shape complementary to one specific antigen, and a constant region (recognised by phagocytes/complement) [1]
(b) Two functions linked to structure [4 marks; 2 each, any two]
- Agglutination: two binding sites per antibody allow it to bind antigens on two different pathogens simultaneously, clumping them together and making them easier to phagocytose [2]
- Neutralisation: the variable region binds an antigen on the pathogen or toxin, blocking it from binding to host cells — preventing infection [2]
- Opsonisation: the antibody coats the pathogen; phagocytes recognise the antibody's constant region via specific receptors, triggering rapid phagocytosis [2]
- Activate complement: binding of the antibody-antigen complex triggers complement proteins that lyse the pathogen [2]
(c) Short-term passive immunity [2 marks]
- The child receives ready-made antibodies passively but does NOT make memory B- or T-cells of its own [1]
- The maternal antibodies are gradually broken down (over weeks to months); without memory cells, immunity is lost as antibodies are lost — the child must encounter the antigen itself, or be vaccinated, for long-term active immunity [1]
Topic 11 Practice — Comprehensive
Mixed practice covering both sub-sections in 9700 P1/P2 style. Try each before revealing the answer.
Which cell type produces large quantities of antibodies during the primary immune response?
- A. Macrophage
- B. T-helper cell
- C. Plasma cell
- D. Memory B-cell
A traveller is bitten by a wild animal in a region where rabies is endemic. They are given an immediate injection of anti-rabies antibodies. What type of immunity does this provide?
- A. Natural active immunity
- B. Natural passive immunity
- C. Artificial active immunity
- D. Artificial passive immunity
A vaccination programme aims to achieve herd immunity in a population. Which statement best describes how herd immunity protects unvaccinated individuals?
- A. Unvaccinated individuals receive antibodies from vaccinated individuals through casual contact
- B. With most of the population immune, the pathogen cannot easily spread, so unvaccinated people are unlikely to encounter an infected person
- C. Vaccinated individuals destroy pathogens in unvaccinated individuals on contact
- D. The vaccine eradicates the pathogen entirely in all individuals, vaccinated or not
HIV (Topic 10) infects T-helper cells, gradually destroying them.
(a) Describe TWO roles of T-helper cells in the immune response. [2]
(b) Explain why a person whose T-helper cell count has fallen significantly may develop opportunistic infections that a healthy person would resist. [4]
(c) Suggest why developing an effective HIV vaccine has been particularly challenging. [3]
(a) Two T-helper roles [2 marks; any two]
- Recognise antigens displayed by macrophages (antigen-presenting cells) and become activated [1]
- Release cytokines that activate B-lymphocytes (which differentiate into plasma cells producing antibodies) [1]
- Release cytokines that activate T-killer cells, which destroy infected body cells [1]
- Stimulate further phagocytosis by macrophages [1]
(b) Why opportunistic infections develop [4 marks]
- T-helper cells are central coordinators of the adaptive immune response — without sufficient numbers, the entire specific immune response is impaired [1]
- B-cells are not effectively activated, so antibody production against new pathogens is reduced [1]
- T-killer cells are not effectively activated, so infected body cells are not destroyed efficiently [1]
- Pathogens that a healthy immune system would clear (e.g. Pneumocystis, certain TB strains) are no longer controlled, causing serious illness — these are "opportunistic" infections that take advantage of the weakened immune system [1]
(c) Challenges in developing an HIV vaccine [3 marks]
- HIV mutates rapidly — its surface antigens change frequently, so a vaccine that works against one strain may not work against a mutated version [1]
- The virus integrates into host DNA, becoming a long-term reservoir that is hard for any immune response to clear [1]
- HIV directly infects the very cells (T-helper cells) that coordinate the immune response, undermining any immune response generated [1]
- The virus exists as multiple strains/clades worldwide, requiring a vaccine effective against many variants [1]
Synoptic note: This question integrates the immune cell roles (Topic 11) with HIV pathogenesis (Topic 10).
Monoclonal antibodies are increasingly used in medicine.
(a) Outline the hybridoma method used to produce monoclonal antibodies. [4]
(b) Explain how monoclonal antibodies can be used to detect human chorionic gonadotrophin (hCG) in a home pregnancy test. [2]
(c) Suggest why monoclonal antibodies used in cancer treatment may produce fewer side effects than traditional chemotherapy. [2]
(a) Hybridoma method [4 marks]
- The target antigen is injected into a mouse, which mounts an immune response producing B-cells specific to the antigen [1]
- B-cells are extracted from the mouse's spleen and fused with myeloma (cancer) cells using a fusion agent — producing hybridoma cells [1]
- Hybridomas combine the antibody-producing ability of the B-cell with the indefinite division ability of the myeloma cell [1]
- Hybridomas are screened to identify those producing the desired antibody, then cultured in large quantities to produce identical (monoclonal) antibodies [1]
(b) Pregnancy test [2 marks]
- Monoclonal antibodies specific to hCG are immobilised on the test strip; if hCG is present in urine, it binds to these antibodies forming antibody-hCG complexes [1]
- The complex triggers a coloured line via a labelled second antibody, indicating pregnancy. Specificity ensures the test responds to hCG only and not to other urine components [1]
(c) Cancer treatment side effects [2 marks]
- Monoclonal antibodies are highly specific to antigens on cancer cells — they bind cancer cells but not healthy cells, so off-target damage is minimised [1]
- Traditional chemotherapy drugs damage all rapidly dividing cells (cancer + healthy hair, gut lining, bone marrow) producing significant side effects; targeting via mAb spares most healthy tissue [1]
Topic 11 — Common Mistakes
- 🧬Saying T-helpers attack pathogens directlyT-helper cells coordinate the immune response by releasing cytokines that activate other cells. They do not directly destroy pathogens or infected cells. T-killer (cytotoxic) cells destroy infected body cells; antibodies (made by plasma cells) target free pathogens.
- ❓Confusing B-cells, plasma cells, and memory B-cellsB-lymphocytes are activated and divide. They differentiate into either plasma cells (short-lived, secrete antibodies) OR memory B-cells (long-lived, ready for next encounter). Don't say "B-cells secrete antibodies" without specifying it's the plasma cell stage.
- 🧸Saying antibodies "kill" pathogens directlyAntibodies do not directly kill pathogens. They bind antigens, then either neutralise (block function), agglutinate (clump), opsonise (mark for phagocytes), or activate complement (which then lyses the pathogen). The killing is done by phagocytes, complement, or T-killer cells — antibodies are the targeting devices.
- 🏭Confusing variable and constant regionsVariable region = unique to each antibody, forms binding site to one specific antigen, located at the tips of the Y arms. Constant region = same across all antibodies of the same class, recognised by phagocytes/complement, located at the stem and lower arm portions. Both are essential and have different functions.
- 🧣Saying antibodies have one binding siteEach antibody has TWO antigen-binding sites — one at the tip of each arm of the Y. Both bind the same antigen (they are identical). The two-site geometry is what allows agglutination — one antibody bridging two pathogens.
- 🤯Confusing active and passive immunityActive = body makes its own antibodies (memory cells produced; long-lasting). Passive = body receives ready-made antibodies (no memory cells; short-lived). Crossing the natural/artificial axis: natural active = recovery from infection; artificial active = vaccination; natural passive = mother to baby; artificial passive = antibody injection.
- 🧴Saying memory cells secrete antibodies during long-term immunityWrong. Memory cells do not secrete antibodies during the resting state. They circulate quietly until antigen is encountered again, at which point they rapidly divide and differentiate into plasma cells (which then secrete antibodies). The long-term immunity is in the existence of memory cells, not in their continuous secretion.
- 🎯Saying the hybridoma method uses the patient's own B-cellsThe B-cells come from a mouse (or other animal) immunised with the target antigen, NOT from the patient. This raises the issue of "humanising" antibodies for clinical use to reduce immune reactions in human patients. Be precise about the cell source.
- ➡Saying vaccines provide passive immunityVaccines provide ACTIVE immunity (artificial active). The body responds to the vaccine antigen by making its own antibodies and memory cells. Vaccines do NOT contain ready-made antibodies. Don't confuse vaccination with antibody injection.
- 🤗Saying herd immunity makes vaccinated people protect others by sharing antibodiesHerd immunity does NOT involve antibody sharing between people. It works by removing susceptible hosts from the population — the pathogen cannot spread efficiently when most people are immune, so even unvaccinated individuals are unlikely to encounter an infected person. Be careful with the mechanism.
- ⚠Saying "antibodies are produced by T-cells"T-cells do NOT produce antibodies. Plasma cells (derived from activated B-cells) produce antibodies. T-cells include T-helper cells (coordinate the response via cytokines) and T-killer cells (destroy infected body cells). The 9700 syllabus limits the T-cell types tested at AS to T-helper and T-killer (cytotoxic).
Topic 11 completes the AS suite. It synthesises Topic 1 (cell biology of immune cells), Topic 2.3 (antibody quaternary structure), Topic 4.1.3 (membrane antigens), Topic 5.1 (clonal expansion via mitosis), and Topic 10 (the diseases that the immune system fights, including HIV which destroys T-helper cells). Highest-yield items: phagocytosis steps with phagosome and phagolysosome, the primary response sequence with macrophage → T-helper → B-cell/T-killer, antibody quaternary structure with variable and constant regions, the four antibody functions (neutralisation, agglutination, opsonisation, complement), the hybridoma method, the four-cell active/passive natural/artificial matrix, vaccine mechanism via primary → memory cells, and the herd immunity concept. Synoptic links to HIV (Topic 10) are heavily favoured by examiners.